Effect of high-fat diet on the pharmacokinetics and safety of flumatinib in healthy Chinese subjects
- PDF / 1,149,617 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 108 Downloads / 232 Views
ORIGINAL ARTICLE
Effect of high‑fat diet on the pharmacokinetics and safety of flumatinib in healthy Chinese subjects Yun Kuang1 · Hui‑ling Song1 · Guo‑ping Yang1,2,3 · Qi Pei4 · Xiao‑yan Yang1 · Ling Ye1 · Shuang Yang1 · Shu‑ting Wu1 · Can Guo1 · Qing‑nan He5,6 · Jie Huang1 Received: 13 November 2018 / Accepted: 19 July 2020 © The Author(s) 2020
Abstract Purpose To evaluate the effect of a high-fat diet on the pharmacokinetics and safety of flumatinib mesylate tablets in healthy Chinese subjects. Methods This study was a randomized, open-label, single-dose, two-period crossover trial in which subjects were randomly assigned to take 400 mg of flumatinib mesylate after a high-fat diet or a fasted state. After a 14-day washout period, the two groups were administered flumatinib mesylate under opposite conditions. Blood samples were collected at baseline 0 and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, and 96 h, respectively. Plasma concentrations of flumatinib and its metabolites (M1 and M3) were analyzed using liquid chromatography-mass spectrometry. Pharmacokinetic parameters were calculated using the non-compartmental module of the Phoenix WinNonlin Version 7.0 software. BE module of WinNonLin was used for statistical analysis of AUC0–t, AUC0–∞ and Cmax in plasma. Results Twelve healthy subjects, half male and half female, were enrolled. One subject withdrew due to a treatment-emergent adverse event. Eleven subjects were administered drugs on fasting and 12 were administered drugs after a high-fat diet. On high-fat diet/fasting, the least square geometric mean (LSGM) ratios of flumatinib, M1, M3, and their 90% confidence interval (CI) were as follows: for flumatinib, Cmax, AUC0–t and AUC0–∞ were 281.65% (225.80–351.31%), 167.43% (143.92– 194.79%), and 166.87% (143.47–194.09%); for M1, Cmax, AUC0–t, and AUC0–∞ were 188.59% (145.29–244.79), 163.94% (149.11–180.24%), and 164.48% (150.36–179.94%); for M3, Cmax, AUC0–t, and AUC0–∞ were 63.47% (54.02–74.57%), 85.23% (74.72–97.22%), and 96.73% (86.63–108.02%). Conclusion Among the subjects, oral administration of 400 mg of flumatinib was safe and well tolerated. High-fat diet significantly increases the exposure to flumatinib, therefore, fasting may be recommended. Clinical trial registration The study was registered at chictr.org Identifier: ChiCTR-IIR-17013179. Keywords Pharmacokinetics · Flumatinib · High-fat diet · Healthy subject
Background
Yun Kuang and Hui-ling Song contributed equally to this work.
Chronic myelogenous leukemia (CML) also called chronic granulocytic leukemia, is a slowly progressing blood and bone marrow disease that usually occurs during or after middle age,
* Qing‑nan He [email protected]
3
XiangYa School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China
* Jie Huang [email protected]
4
Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China
5
Research Center for Drug Clinical Evaluation of Central, Central South Univer
Data Loading...
